NasdaqGM:KYMRBiotechs
How Kymera’s Bigger Losses and New Equity Plans May Impact Kymera Therapeutics (KYMR) Investors
In late February 2026, Kymera Therapeutics reported a wider full-year 2025 net loss of US$311.35 million and loss per share of US$3.69, while simultaneously filing a US$392.14 million shelf registration linked to an ESOP offering and a US$500 million at-the-market equity program.
Alongside these financings, Kymera advanced its oral STAT6 and IRF5 degrader programs, added veteran developer Neil Graham as Chief Development Officer, and maintained strong backing from major pharma collaborators...